Skip to main content

Around 30 centres and hospitals in Catalonia are studying promising treatments of COVID-19

5 May 20




Press and Communications Officer
Tel.+34 93 40 37255

The “Corporación Catalana de Medios Audiovisuales” has published a report on the RiPCoN project, in which IRB Barcelona’s Structural Bioinformatics and Network Biology is participating. Headed by Patrick Aloy, this lab is conducting a computational study of the interactions between the coronavirus and human cells with the aim to identify drugs already on the market or under development that can tackle the spread of the virus. The goal is to identify an antiviral treatment and, in the long-term, a possible vaccine.

In addition, various media have reported on  the efforts made by IRB Barcelona to conduct mass screening for the disease.

Link to: CCMA

Link to: CCMA

Link to: La Vanguardia

Link to: ABC


About IRB Barcelona

Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 27 laboratories and eight core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. It is located in the Barcelona Science Park. IRB Barcelona is a CERCA center, and a member of the Barcelona Institute of Science and Technology (BIST).